UK Pharmacovigilance Obligations During Clinical Development
UK Pharmacovigilance Obligations During Clinical Development Understanding Pharmacovigilance Obligations During UK Clinical Development Pharmacovigilance (PV) obligations during clinical development are designed to protect participants and ensure the integrity of safety data. In the United Kingdom (UK), the Medicines and Healthcare products Regulatory Agency (MHRA) enforces strict requirements for adverse event (AE), serious adverse event (SAE),…
Read More “UK Pharmacovigilance Obligations During Clinical Development” »